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Summary
Multiple myeloma (MM) is a neoplastic disease characterized by proliferation and prolonged survi-
val of clonal plasma cells, most frequently occurring in the bone marrow, but also in other tissues. 
Dendritic cells (DCs) are a heterogeneous population of leukocytes defined as professional antigen 
presenting cells playing a key role in anticancer immunity. The purpose of this study was to evaluate 
subpopulations of myeloid and lymphoid DCs in the peripheral blood (PB) and bone marrow (BM) 
of patients with MM in the different clinical stages of MM and in correlation with known progno-
stic factors. The study involved 50 patients diagnosed with MM before the initiation of anticancer 
therapy and 25 individuals belonging to the control group. The mean percentage of myeloid and 
lymphoid DCs was determined using flow cytometry. In the present study, we demonstrated a si-
gnificant reduction in the percentages of both myeloid and lymphoid DCs in MM patients, more 
pronounced in those with the worse prognosis as determined by the high levels of β2 microglobulin. 
Accordingly, a marked decrease in the proportions of both myeloid and lymphoid DCs in the BM of 
patients with advanced clinical stage (III) compared to earlier stages (I+II) was also found. Our re-
sults suggest that the degree of DC subpopulations deficit could be related to the MM progression, 
which in consequence may contribute to the MM-related impairment of the immune responses. 
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IntroductIon
Multiple myeloma (MM) is a neoplastic disease cha-
racterized by proliferation and prolonged survival of 
clonal plasma cells, most frequently occurring in the 
bone marrow, but also in other tissues. Neoplastic pla-
smocytes usually produce one type of immunoglobulin 
– a monoclonal protein (M protein). Multiple myeloma 
accounts for approximately 1% of all cancers and 14% 
of hematological malignancies. It usually affects older 
people, especially men. Symptoms of the disease inclu-
de bone destruction with pathological fractures, kid-
ney failure and frequent infections, which are among 
the major causes of patient mortality [1,2]. 
There are two main staging systems to determine the 
disease stage: the Durie-Salmon staging system and the 
International Staging System (ISS). The Durie-Salmon 
clinical staging system incorporates several factors 
correlating with tumor cell mass. Using this method, 
stage is determined based upon a subjective measure 
of tumor cell density in the bone marrow along with 
measures of end organ damage (renal insufficiency, 
anemia, hypercalcemia, lytic bone lesions) and im-
munoglobulin burden [8]. ISS is based on the levels of 
serum beta-2 (b2) microglobulin and serum albumin, 
and divides the disease into three stages with progno-
stic significance [10]. The serum b2 microglobulin level 
is elevated (i.e., >2.7 mg/L) in 75% of patients at the 
time of diagnosis. Patients with high values have in-
ferior survival [25].
Multiple myeloma is associated with immunosuppres-
sion that is responsible for both the impaired anti-tu-
mor response and the aforementioned frequent and 
recurrent infections. It was primarily found that im-
mune defects in MM patients included abnormalities 
in the number and function of B, T and NK cells [14]. 
More recent data revealed convincing evidence on the 
important role of dendritic cells (DCs) in the impair-
ment of the immune system [26].
Dendritic cells are a heterogeneous population of leu-
kocytes defined as professional antigen presenting 
cells. They are capable of presenting both exogenous 
antigens as well as autoantigens. DCs perform a funda-
mental role in the activation of the immune responses, 
both innate and specific. Dendritic cells express on 
their surface the following antigens: CD1a, CD40, CD54, 
CD58, CD80, CD83, CD86, DC-SIGN. They are characte-
rized by high expression of MHC class I and II [3,5,13]. 
There are two major subpopulations of DCs: myeloid 
and lymphoid (plasmacytoid). DCs occur in almost all 
tissues of the body. In respect of anatomic location, 
maturity and activation state they are morphologically 
and functionally divergent [2,5,19,28]. Lymphoid DCs 
stimulate the differentiation of Th0 lymphocytes into 
Th2, thus inducing a humoral response [15]. Myeloid 
DCs direct differentiation of Th0 cells towards Th1 and 
Th17, and induce a cellular response [17]. It should 
be noted that lymphoid DCs secrete INF-α and IFN-β, 
which affect the activation of T CD8+ and NK cells [23]. 
For this reason, it is difficult to distinguish between the 
functions of myeloid and lymphoid dendritic cells [13]. 
The degree of DCs’ maturity is also important for the-
ir functions. Mature DCs induce an immune response, 
whereas the immature cells may lead to the develop-
ment of tolerance to specific antigens [16]. Factors that 
inhibit maturation of DCs include cytokines, such as 
IL-10 secreted by tumor cells [21]. Also IL-6 and VEGF, 
high serum levels of which are observed in patients 
with multiple myeloma, inhibit differentiation and ma-
turation of dendritic cells [9,12,22].
The purpose of this study was to evaluate subpopula-
tions of myeloid (BDCA-1+) and lymphoid (BDCA-2+) 
DCs in the PB and BM of patients with MM in different 
clinical stages and in correlation with known progno-
stic factors: serum b2 microglobulin level and albumin 
concentration.
MaterIal and Methods
Study and control group
The study involved 50 patients diagnosed with MM at 
the Department of Hematology in the Holycross Can-
cer Centre in Kielce. The research samples were col-
lected after the MM diagnosis before the initiation of 
anticancer therapy.
The average age of patients was 64 (ranging from 34 
to 81). In the study group, there were 27 women and 
23 men.
The diagnosis of multiple myeloma was based on the 
criteria of the International Myeloma Working Group. 
At the time of diagnosis patients were staged according 
to the Durie-Salmon classification, as follows: stage 
I – 14 patients, stage II – 8 patients and stage III – 28 
patients. The research protocol was approved by the 
Ethics Committee of the Medical University of Lublin 
and all patients gave written informed consent.
Patients with the coexistence of other chronic diseases, 
such as allergic diseases, autoimmune diseases, other 
cancer diseases, serious infections, as well as those 
treated with immunosuppressants and immunomo-
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dulators or receiving transfusion of blood products in 
the past 6 months, were excluded from the study. The 
control group consisted of 25 subjects (15 women and 
10 men) undergoing hip replacement surgery due to 
osteoarthritis, from whom bone marrow and periphe-
ral blood samples were collected at the time of surgery. 
The median age of subjects in the control group was 
63.7 (ranging from 33 to 79).
cytoMetrIc analysIs of MyeloId and lyMphoId dcs 
Peripheral blood and bone marrow samples were col-
lected into heparinized tubes and immediately proces-
sed. Peripheral blood and bone marrow mononuclear 
cells (PBMCs and BMMCs, respectively) were separated 
by density gradient centrifugation. After isolation, the 
cells were surface-labeled with the following monoclo-
nal antibodies (MoAbs) conjugated with relevant flu-
orochromes: anti-CD45/FITC and anti-CD14/RPE (in or-
der to determine precisely the goal for a population of 
mononuclear cells), anti-BDCA-1/FITC and anti-CD19/
PE-Cy5 (to estimate the percentage of immature my-
eloid DCs), and anti-BDCA-2/FITC and anti-CD123/RPE 
(to determine the frequency of immature lymphoid 
DCs). PBMCs and BMMCs with the phenotype BDCA-
1+CD19- were considered to be myeloid DCs, whereas 
those presenting phenotype BDCA2+CD123+ were assi-
gned to lymphoid DCs. Labeled cells were washed and 
analyzed with the flow cytometer (BD FACSCalibur). 
In each case, staining was compared with that of the 
appropriately labeled isotype control antibody. 
statIstIcal analysIs
Statistical analysis of the results was conducted using 
Statistica 9.0. Deviation from normality was evaluated 
by Kolmogorov–Smirnov test. Data were expressed as 
the mean value ± SD, median, minimum and maximum. 
Differences between groups were assessed using the 
Mann–Whitney U test. Pearson or Spearman corre-
lation analyses were used to analyze the correlation. 
A value p less than 0.05 was considered statistically 
significant.
results
Assessment of the DC subsets in the peripheral 
blood (PB)
In PB, the value of the mean percentage of myeloid DCs 
of MM patients was 0.15±0.13% (median 0.13%, min. 
0.02%, max. 0.63%), and was significantly lower than 
corresponding cells in the control group – 0.55±0.22% 
(median 0.55%, min. 0.18%, max. 1.00%) (p=0.000001) 
(Figure 1). Similarly, we found the mean frequency 
of lymphoid DCs of MM patients markedly dimini-
shed compared to that observed in the control group 
– 0.13±0.13% (median 0.11%, min. 0.01%, max. 0.6%) 
vs. 0.4±0.25% (median 0.37%, min. 0.15%, max. 1.04%) 
(p=0.00005) (Figure 2).
Assessment of DC subsets in bone marrow (BM)
The mean percentage of BM myeloid DCs from MM pa-
tients was significantly lower compared to correspon-
ding cells isolated from the control group – 0.12±0.09% 
(median 0.1%, min. 0.01%, max. 0.54%) vs. 0.27±0.09% 
(median 0.25%, min. 0.16, max. 0.4) (p=0.000009) (Figu-
re 3). Similarly, the mean proportion of lymphoid DCs 
isolated from the BM of MM patients was markedly lo-
wer compared to those isolated from the control group 
– 0.23±0.22% (median 0.15%, min. 0.02%, max. 0.84%) 
vs. 0.9±0.88% (median 0.53%, min. 0.2%, max. 3.57%) 
(p=0.00005) (Figure 4).
Fig. 1.  Median percentage of myeloid DCs in the PB of MM patients and control subjects
Fig. 2.  Median percentage of lymphoid DCs in the PB of MM patients and control 
subjects929
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correlatIons between dcs subsets and prognostIc factors 
Assessment of DC subsets in relation to serum 
concentration of β2 microglobulin in MM patients
There was a significant inverse correlation between β2 
microglobulin serum concentrations and the percentages 
of myeloid (p=0.002, r=-0.5) as well as lymphoid (p=0.003, 
r=-0.48) DCs in patients’ PB (Figure 5 and Figure 6, respec-
tively). In BM, such a negative correlation was observed 
only when we evaluated the frequencies of myeloid DCs 
in the context of serum levels of this prognostic factor 
(p=0.0004, r=-0.56) (Figure 7).
Assessment of DC subsets in relation to albumin 
concentrations in sera of MM patients
Although in the group of patients with less advanced MM 
(stage I+II) the value of the mean albumin concentration 
Fig. 3.  Median percentage of myeloid DCs in the BM of MM patients and control subjects
Fig. 4.  Median percentage of lymphoid DCs in the BM of MM patients and control 
subjects
Fig. 5.  The correlation between the percentages of myeloid DCs in PB of MM patients 
and serum levels of β2 microglobulin
Fig. 6.  The correlation between the percentages of lymphoid DCs in the PB of MM 
patients and serum levels of β2 microglobulin
Fig. 7.  The correlation between the percentages of myeloid DCs in the BM of MM 
patients and serum concentration of β2 microglobulin930
Postepy Hig Med Dosw (online), 2013; tom 67: 926-932
was 3.58 g/L (median 3.49 g/L, min. 2.32 g/L, max. 4.97 
g/L), and was lower than in patients with more advanced 
MM (mean 4.16 g/L, median 4.14 g/L, min. 3.59 g/L, max. 
4.72 g/L), the difference was only of borderline signifi-
cance (p=0.06). Nevertheless, we did not find any stati-
stically significant correlations between the percentages 
of DC subsets and albumin concentrations either in the 
PB or in the BM. 
correlatIon of dc subsets wIth clInIcal stage of MM 
We found that only frequencies of DCs isolated from BM 
correlated with the clinical stage of MM. In particular, the 
mean proportion of myeloid DCs from BM of patients in 
stage III (according to the Durie-Salmon classification) 
was significantly lower in comparison with the corre-
sponding cells of patients in stages I and II – 0.09±0.042% 
(median 0.098%, min. 0.064%, max. 0.14%) vs. 0.15±0.83% 
(median 0.17%, min. 0.09%, max. 0.196%) (p=0.02) (Figure 
8). A similar dependence concerning the mean percen-
tage of lymphoid DCs in BM was observed – 0.12±0.08% 
(median 0.1%, min. 0.07%, max. 0.18%) vs. 0.32±0.93% (me-
dian 0.29%, min. 0.16%, max. 0.46%) (p=0.01) (Figure 9).
dIscussIon
Disorders of the immune system play an important role 
both in the pathogenesis and clinical course of MM, be-
ing responsible not only for the increased incidence of 
infections, but also for the disease progression. Dendritic 
cells constitute one of the key populations in the immu-
ne system. In patients with solid tumors as well as with 
hematological malignancies, many abnormalities in the 
number and function of DCs were described. However, still 
little is known about the changes in DC subpopulations 
in patients with MM.
In the present study we found significantly reduced per-
centages of myeloid and lymphoid DCs in both PB and BM 
of MM patients compared to the healthy subjects. Similar 
results concerning a marked decrease in the percentages 
of both DC subpopulations in the PB of MM patients were 
described by Kovarova et al. [18], Do et al. [7], and Martin-
-Ayuso et al. [20]. Of note, the latter authors found that 
the amount of DC precursors in the PB of MM patients 
was unchanged [20]. It should be emphasized, however, 
that data on the evaluation of DC subpopulations in the 
BM of MM patients are still lacking.
There are many potential explanations for the reduction 
in the percentages of DCs in the PB and BM of patients 
with MM. It has been shown that IL-6 inhibits the forma-
tion of colonies of DC progenitor cells and DC maturation 
[24] Another factor adversely affecting the formation 
and maturation of dendritic cells is VEGF [4]. It has been 
shown on animal models as well as in clinical observation 
that a high concentration of VEGF reduces the percenta-
ge of circulating peripheral blood DCs, and impairs their 
functions [9]. Yang et al. demonstrated that neutralization 
of VEGF restores the normal function of DCs in patients 
with MM [30].
Next, we found a significant inverse correlation betwe-
en serum concentrations of β2 microglobulin of MM pa-
tients and the proportions of both myeloid and lymphoid 
DCs in the PB as well as with the frequencies of myeloid 
DCs in the BM. Since β2 microglobulin is one of the most 
important negative prognostic factors in MM correla-
ting with disease activity [6,25], the lower percentages 
of both DC subpopulations seen in patients with higher 
concentration of β2 microglobulin might reflect greater 
disorders in the immune system in more aggressive co-
urse of the disease. To date, there are only a few reports 
Fig. 8.  Median percentage of myeloid DCs in the BM of MM patients in stage I and II 
compared to stage III according to Durie-Salmon staging system
Fig. 9.  Median percentage of lymphoid DCs in the BM of MM patients in stage I and II 
compared to stage III according to Durie-Salmon staging system931
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on the relationship between the frequency of DCs and 
the serum concentration of β2 microglobulin. Xie et al. 
observed an inhibitory effect of β2 microglobulin on DCs 
and their capacity for T cell stimulation [29]. On the other 
hand, Wang et al. demonstrated that the bone marrow 
microenvironment occupied by MM cells might affect 
DCs as well [27]. They also demonstrated that the addi-
tion of antibodies against IL-6, IL-10 and TGF-β to a cul-
ture containing DC colonies and particular factors of BM 
microenvironment could partly restore the function of 
DCs [27]. Thus, it seems that both the MM cells and the 
increased serum concentration of β2 microglobulin might 
disturb the subpopulations of DCs either in the BM or PB.
Additionally, we assessed DC subpopulations in PB and 
BM of patients in different clinical stages according to 
the Durie-Salmon classification. Although a more pro-
nounced decrease in both studied DC subsets was noted 
in the PB from patients with the most advanced dise-
ase, the differences did not reach statistical significance, 
when compared to earlier stages. Our observation is con-
sistent with the previous data published by Ratta et al. 
[24]. In turn, Harrison et al. found that disorders of DCs 
in patients with monoclonal gammopathy of undeter-
mined significance (MGUS) are extremely rare, whereas 
in MM patients these changes are frequently observed 
[12]. This suggests that the progression of MGUS to MM 
might correspond with the increasing adverse influence 
of MM cells on DC subpopulations. In the present study, 
we originally found that the frequency of both myeloid 
and lymphoid DCs in the BM was significantly lower in 
the patients in stage III compared to the patients in the 
less advanced disease, which may confirm the previous 
report by Wang et al., suggesting a direct adverse effect 
of the BM microenvironment on DCs [27].
In summary, herein we demonstrated the reduction in 
the percentages of both myeloid and lymphoid DCs in 
MM more pronounced in those with the worse progno-
sis as determined by higher levels of β2 microglobulin. 
This observation may reflect more severe disorders in 
DC populations in patients with more active disease. It 
also seems that factors secreted by the MM plasmocytes 
or tumor microenvironment negatively affect the DCs, 
which is manifested by a decrease in the frequency of 
both myeloid and lymphoid DCs in the BM isolated from 
patients at an advanced clinical stage in comparison with 
patients at earlier stages. The ultimate role played by DCs 
in the development of MM is still unexplained and requ-
ires further studies.
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